Net Income on Higher Margins for Quarter, Six Months; Positive Free
Cash Flows POWAY, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Digirad
Corporation (NASDAQ:DRAD), a leading provider of diagnostic imaging
systems and services to physicians' offices, hospitals and other
medical services providers, today reported net income of $238,000,
after stock-based compensation expense, for the second quarter
ended June 30, 2007, compared to a net loss of $1.2 million for
second-quarter 2006. For six months, the Company reported net
income of $312,000, after stock-based compensation expense,
compared to net losses of $4.0 million for the same period a year
ago. Chief Executive Mark Casner commented: "We are pleased to
report improved earnings, including our second consecutive quarter
of profitability, and a return to positive free cash flow. Revenues
are also in a sequential quarterly growth trend. That said,
accelerating revenue growth is our principal focus. We are also
pleased to note the integration of recently acquired Ultrascan, our
first step in diversifying our business, is progressing according
to plan." Consolidated revenues for the quarter were $18.8 million,
compared to $19.0 million for second-quarter 2006. DIS revenue,
including revenue from our May 1, 2007, acquisition of Ultrascan,
was $13.3 million, which included no stress agent sales, compared
to DIS revenue for second-quarter 2006 of $13.4 million, which
included stress agent revenue of $854,000. For the quarter, DIS
operated 130 units in service with an overall asset utilization
rate of 60%, compared to 80 units in service and an asset
utilization rate of 60% for second-quarter 2006, before the
Ultrascan acquisition. Digirad management is using the asset
utilization metric to track the productivity of its DIS assets and
drive improved margins. Product-related revenues, which include
camera sales and maintenance revenue, were $5.5 million and
included sales of 19 cameras for the quarter, compared to $5.6
million, including sales of 19 cameras, for second-quarter 2006.
Casner continued: "We believe that Ultrascan-related augmentation
of DIS' services platform, continuing upgrades of DIS' fleet of
mobile cameras and higher utilization of these added resources will
position us to generate growth of services revenues. We are also
optimistic about the anticipated effects of our marketing
initiatives, which include our efforts to form strategic alliances
with centers of influence such as academic institutions and medical
centers, to build awareness of Digirad services by supporting the
imaging needs of local-area practitioners." Consolidated gross
profit for the quarter improved to $5.8 million, or 30.9% of
revenues, from $5.7 million, or 29.8% of revenues, for the second
quarter of 2006. DIS gross margin improved to 27.4% of revenue,
compared to 25.6% for second-quarter 2006. Product-related gross
margin was 39.2%, compared to 39.8% for the second quarter of 2006.
Casner added: "During the quarter we continued to upgrade our DIS
nuclear fleet of 87 cameras by replacing 15 cameras with the
advanced multi-headed Cardius XPO configuration. Forty-two
multi-headed mobile cameras are now in operation, and we expect to
complete the upgrade within the next 18 months. We believe that the
enhanced reliability and higher throughput of multi-headed cameras,
and the higher productivity and shorter workdays they can achieve,
enable us to reduce labor costs. This quarter's results support our
belief that this program can deliver the productivity and cost
benefits we anticipate for our DIS business." Operating expenses
for the quarter declined $1.3 million to $6.0 million from $7.3
million in second- quarter 2006. "Cost control remains a high
priority," Casner stated. Net income for the quarter was $238,000,
or $0.01 per share, after accounting for stock-based compensation
expense of $351,000, compared to a net loss of $1.2 million, or
$(0.06) per share, including stock-based compensation expense of
$574,000. For six months ended June 30, 2007, consolidated revenues
were $36.4 million, compared to $38.0 million for the first six
months of 2006. DIS revenue for the period was $25.5 million,
compared to $26.6 million for six-months 2006, and product-related
revenues were $10.8 million, compared to $11.4 million in the prior
period. Consolidated gross margin for six months improved to 31.0%
from 26.5% for the same period last year. Net income for six months
was $312,000, or $0.02 per share, including stock-based
compensation expense of $625,000, compared to a net loss of $4.0
million, or $(0.21) per share, including stock-based compensation
expense of $1.0 million, for the same period in 2006. Cash and
equivalents and securities available for sale on June 30, 2007,
totaled $32.2 million, compared to $44.3 million on December 31,
2006. Cash usage in second-quarter 2007 included the $7.25 million
acquisition of Ultrascan and repayment in full of $1.5 million of
assumed debt which was offset in part by positive operating cash
flows of $1.2 million. Net receivables were $9.7 million on June
30, 2007, compared to $7.5 million on December 31, 2006, the
increase being largely attributable to acquiring Ultrascan
receivables. Net inventories were $6.0 million on June 30, 2007
compared to $5.9 million on December 31, 2006. Management Reaffirms
2007 Guidance Reflecting the results for the first half of the year
and the integration of Ultrascan, Digirad anticipates consolidated
revenues for 2007 in the range of $77 million to $80 million,
consisting of DIS revenue between $54 million and $56 million and
product revenue between $23 million and $24 million; and
consolidated net losses ranging from $500,000 to $2.5 million,
including estimated stock-based compensation expense of $1.1
million. Digirad anticipates no stress agent revenue for 2007
versus stress agent revenue of $2.0 million for 2006. Conference
Call Information Digirad has scheduled a conference call at 11:00
a.m. EDT today. A simultaneous webcast of the call may be accessed
online from the Events & Presentations link on the Investor
Relations page at http://www.digirad.com/; an archived replay of
the webcast will be available within 15 minutes of the end of the
conference call. A telephone replay of the call will be available
at (800) 406-7325 or (303) 590-3030, conference ID #3764151, from
approximately 2 p.m. EDT. The telephone replay will be available
until 11:59 pm EDT on August 8. About Digirad Digirad Corporation
provides diagnostic nuclear and ultrasound imaging systems and
services to physicians' offices, hospitals and other medical
services providers for cardiac, vascular, and general imaging
applications. Digirad's Cardius XPO line of nuclear imaging cameras
use patented solid-state technology and unique multi (single, dual,
triple) head design for superior performance and advanced features
for sharper digital images, faster processing, compact size,
lighter weight for portability, ability to handle patients up to
500 pounds, and improved patient comfort compared to standard
nuclear cameras. Digirad's 2020tc general-purpose nuclear imager
has a small footprint and may also be configured for fixed or
mobile use to supplement primary imaging. Digirad's installed base
of equipment exceeds 450 systems; in addition, a mobile fleet of
more than 120 nuclear and ultrasound imaging systems is being used
in 22 states, primarily in the eastern, midwestern and southwestern
United States. For more information, please visit
http://www.digirad.com/. Digirad(R), Digirad Imaging Solutions(R),
and Cardius(R) are registered trademarks of Digirad Corporation.
Forward-Looking Statements Digirad cautions that statements
included in this press release that are not a description of
historical facts are forward-looking statements. You can identify
these statements by the fact that they do not relate strictly to
historical or current facts and use words such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" and
other words and terms of similar meaning in connection with a
discussion of future operating or financial performance or events.
Examples of such statements include the statements regarding our
expectations of gross margin improvements and declining operating
expenses in both DIS and the product business; our belief that the
Utlrascan acquisition is complementary to our DIS business and
provides opportunities for the creation of future growth and
positive financial performance; our expectations of improved
performance and lower costs from our upgrade of the DIS fleet to
the mobile version of the Cardius 3 XPO system, improved
utilization of DIS assets and our efforts to form strategic
alliances with centers of influence;; our expectations of achieving
reduced operating costs as a result of cost cutting measures; and,
in general, our anticipated financial results for 2007. The
inclusion of these and other forward-looking statements should not
be regarded as a representation by Digirad that any of its plans
will be achieved. Actual results may differ materially from those
set forth in this press release due to the risks and uncertainties
inherent in Digirad's business including, without limitation: the
degree to which personnel changes and related disruptions in our
business activities may affect Digirad's products, customers, work
force, suppliers, and our overall business prospects and
operations; the degree to which Digirad's camera systems and
related services will be accepted by physicians and hospitals some
of whom may experience reliability issues or technical problems;
the ability of Digirad effectively to market, sell and distribute
its medical devices, and related services given its limited
capabilities in these areas; Digirad's ability to manage risks
relating to product liability, warranty claims, recalls, property
damage and personal injury with respect to its imaging systems; and
other risks detailed in Digirad's Securities and Exchange
Commission filings, including its Annual Report on Form 10-K and
other reports filed with the Securities and Exchange Commission.
Given these uncertainties, readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Digirad undertakes
no obligation to revise or update this press release including the
forward-looking statements contained herein to reflect events or
circumstances after the date hereof or to update the reasons actual
results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Digirad Corporation Condensed Consolidated
Statements of Operations (In thousands, except per share amounts)
(Unaudited) Three Months Ended Six Months Ended June 30, June 30,
2007 2006 2007 2006 Revenues: DIS $13,323 $13,403 $25,520 $26,620
Product 5,489 5,619 10,830 11,357 Total revenues 18,812 19,022
36,350 37,977 Cost of revenues: DIS 9,667 9,967 18,605 20,399
Product 3,335 3,383 6,493 7,513 Total cost of revenues 13,002
13,350 25,098 27,912 Gross profit 5,810 5,672 11,252 10,065
Operating expenses: Research and development 791 1,117 1,573 2,213
Sales and marketing 1,939 2,066 4,037 4,525 General and
administrative 3,117 4,105 6,089 8,234 Amortization of intangible
assets 103 20 109 29 Total operating expenses 5,950 7,308 11,808
15,001 Loss from operations (140) (1,636) (556) (4,936) Interest
and other, net 378 433 868 929 Net income (loss) $238 $(1,203) $312
$(4,007) Net income (loss) per share - basic and diluted $0.01
$(0.06) $0.02 $(0.21) Weighted average shares outstanding: Basic
18,821 18,761 18,818 18,736 Diluted 19,208 18,761 19,208 18,736
Stock-based compensation expense is included in the above as
follows: Cost of DIS revenue $19 $71 $44 $91 Cost of Product
revenue 17 23 43 41 Research and development 21 47 44 89 Sales and
marketing 15 74 65 149 General and administrative 279 359 429 675
Digirad Corporation Condensed Consolidated Balance Sheets (in
thousands) June 30, Dec. 31, 2007 2006(1) (Unaudited) Assets Cash
and cash equivalents $9,826 $10,070 Securities available-for-sale
22,394 34,256 Accounts receivable, net 9,704 7,534 Inventories, net
6,020 5,860 Other current assets 1,097 1,499 Total current assets
49,041 59,219 Property and equipment, net 14,418 9,570 Other
intangible assets, net 3,219 428 Goodwill 2,699 -- Restricted cash
60 60 Total assets $69,437 $69,277 Liabilities and stockholders'
equity Accounts payable $2,011 $2,643 Accrued compensation 3,348
3,650 Accrued warranty 949 788 Other accrued liabilities 3,274
3,306 Deferred revenue 2,865 2,775 Current portion of long-term
debt 262 269 Total current liabilities 12,709 13,431 Long-term
debt, net of current portion 5 99 Deferred rent 268 302 Total
stockholders' equity 56,455 55,445 Total liabilities and
stockholders' equity $69,437 $69,277 (1) The condensed consolidated
balance sheet as of December 31, 2006, was derived from the audited
financial statements as of that date. DATASOURCE: Digirad
Corporation CONTACT: Investors, Dan Matsui, or media, Len Hall,
both of Allen & Caron, for Digirad Corporation,
+1-949-474-4300; or Todd Clyde, Chief Financial Officer of Digirad
Corporation, +1-858-726-1600 Web site: http://www.digirad.com/
Copyright
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Jul 2023 to Jul 2024